PIK3CA mutations predict resistance to trastuzumab/pertuzumab and nab-paclitaxel in primary HER2-positive breast cancer - Massive parallel sequencing analysis of 293 pretherapeutic core biopsies of the GeparSepto study

被引：0
|
作者：
Loibl, S.
Budczies, J.
Weichert, W.
Furlanetto, J.
Stenzinger, A.
Pfarr, N.
von Minckwitz, G.
Jackisch, C.
Schneeweiss, A.
Fasching, P.
Schmatloch, S.
Aktas, B.
Nekljudova, V.
Weber, K.
Untch, M.
Denkert, C.
机构：
[1] German Breast Grp, Neu Isenburg, Germany
[2] Charite, Berlin, Germany
[3] Univ Hosp Heidleberg, Heidelberg, Germany
[4] Sana Klinikum Offenbach, Offenbach, Germany
[5] Univ Hosp Erlangen, Erlangen, Germany
[6] Elisabeth Krankenhaus Kassel, Kassel, Germany
[7] Univ Hosp Sen, Essen, Germany
[8] Helios Kliniken Berlin Buch, Berlin, Germany
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.SABCS15-P3-07-03
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3-07-03
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase 2 prospective open label study of neoadjuvant nab-paclitaxel, trastuzumab, and pertuzumab in patients with HER2-positive primary breast cancer
    Lavasani, Sayeh M.
    Somlo, George
    Yost, Susan E.
    Frankel, Paul H.
    Ruel, Christopher
    Cui, Yujie
    Murga, Mireya
    Tang, Aileen
    Martinez, Norma
    Kruper, Laura
    Tumyan, Lusine
    Schmolze, Daniel
    Yeon, Christina
    Yuan, Yuan
    Waisman, James R.
    Mortimer, Joanne
    CANCER, 2023, 129 (05) : 740 - 749
  • [2] Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab
    Cizkova, M.
    Dujaric, M-E
    Lehmann-Che, J.
    Scott, V.
    Tembo, O.
    Asselain, B.
    Pierga, J-Y
    Marty, M.
    de Cremoux, P.
    Spyratos, F.
    Bieche, I.
    BRITISH JOURNAL OF CANCER, 2013, 108 (09) : 1807 - 1809
  • [3] Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab
    M Cizkova
    M-E Dujaric
    J Lehmann-Che
    V Scott
    O Tembo
    B Asselain
    J-Y Pierga
    M Marty
    P de Cremoux
    F Spyratos
    I Bieche
    British Journal of Cancer, 2013, 108 : 1807 - 1809
  • [4] PIK3CA mutations in primary HER2-positive and triple negative breast cancer.
    Loibl, Sibylle
    Denkert, Carsten
    Loi, Sherene
    Andre, Fabrice
    Mueller, Berit
    Schneeweiss, Andreas
    Blohmer, Jens U.
    Jackisch, Christian
    Guo Sanxing
    Gade, Stephan
    Fasching, Peter A.
    Schem, Christian
    Sotiriou, Christos
    Untch, Michael
    Von Minckwitz, Gunter
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [5] PIK3CA mutations in HER2-positive breast cancer: an ongoing conundrum
    Goel, S.
    Krop, I. E.
    ANNALS OF ONCOLOGY, 2016, 27 (08) : 1368 - 1372
  • [6] A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)
    Patel, Tejal A.
    Ensor, Joe E.
    Creamer, Sarah L.
    Boone, Toniva
    Rodriguez, Angel A.
    Niravath, Poly A.
    Darcourt, Jorge G.
    Meisel, Jane L.
    Li, Xiaoxian
    Zhao, Jing
    Kuhn, John G.
    Rosato, Roberto R.
    Qian, Wei
    Belcheva, Anna
    Schwartz, Mary R.
    Kaklamani, Virginia G.
    Chang, Jenny C.
    BREAST CANCER RESEARCH, 2019, 21 (01)
  • [7] A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)
    Tejal A. Patel
    Joe E. Ensor
    Sarah L. Creamer
    Toniva Boone
    Angel A. Rodriguez
    Poly A. Niravath
    Jorge G. Darcourt
    Jane L. Meisel
    Xiaoxian Li
    Jing Zhao
    John G. Kuhn
    Roberto R. Rosato
    Wei Qian
    Anna Belcheva
    Mary R. Schwartz
    Virginia G. Kaklamani
    Jenny C. Chang
    Breast Cancer Research, 21
  • [8] Phase II, randomized, parallel-cohort study of neoadjuvant buparlisib (BKM120) in combination with trastuzumab and paclitaxel in women with HER2-positive, PIK3CA mutant and PIK3CA wild-type primary breast cancer - NeoPHOEBE
    Loi, S.
    Loibl, S.
    Di Cosimo, S.
    Nekljudova, V.
    Flamen, P.
    Saini, K. S.
    Michiels, S.
    de la Pena, L.
    Nanni, S.
    Urban, P.
    Piccart, M.
    von Minckwitz, G.
    Baselga, J.
    CANCER RESEARCH, 2013, 73
  • [9] Phase II, randomized, parallel-cohort study of neoadjuvant buparlisib (BKM120) in combination with trastuzumab and paclitaxel in women with HER2-positive, PIK3CA mutant and PIK3CA wild-type primary breast cancer - NeoPHOEBE
    Loibl, S.
    de la Pena, L.
    Nekljudova, V.
    Zardavas, D.
    Michiels, S.
    Denkert, C.
    Rezai, M.
    Bermejo, B.
    Lee, S-C
    Turri, S.
    Urban, P.
    Kuemmel, S.
    Lux, M.
    Piccart, M.
    von Minckwitz, G.
    Baselga, J.
    Loi, S.
    CANCER RESEARCH, 2016, 76
  • [10] PIK3CA mutations in HER2-positive early breast cancer patients enrolled in the adjuvant randomized short-HER study
    Guarneri, V.
    Dieci, M. V.
    Bisagni, G.
    Brandes, A. A.
    Frassoldati, A.
    Cavanna, L.
    Musolino, A.
    Giotta, F.
    Rimanti, A.
    Garrone, O.
    Bertone, E.
    Cagossi, K.
    Nanni, O.
    Piacentini, F.
    Orvieto, E.
    Curtarello, M.
    Chic, N.
    D'Amico, R.
    Prat, A.
    Conte, P. F.
    ANNALS OF ONCOLOGY, 2020, 31 : S23 - S23
12345